These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 17661414

  • 21. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values.
    Amarapurkar DN, Patel ND.
    Trop Gastroenterol; 2004; 25(3):130-4. PubMed ID: 15682660
    [Abstract] [Full Text] [Related]

  • 22. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy.
    Kopec KL, Burns D.
    Nutr Clin Pract; 2011 Oct; 26(5):565-76. PubMed ID: 21947639
    [Abstract] [Full Text] [Related]

  • 23. Pathogenesis of nonalcoholic steatohepatitis (NASH).
    Ma X, Li Z.
    Chin J Dig Dis; 2006 Oct; 7(1):7-11. PubMed ID: 16412031
    [Abstract] [Full Text] [Related]

  • 24. Nonalcoholic fatty liver disease.
    Hjelkrem MC, Torres DM, Harrison SA.
    Minerva Med; 2008 Dec; 99(6):583-93. PubMed ID: 19034256
    [Abstract] [Full Text] [Related]

  • 25. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM.
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [Abstract] [Full Text] [Related]

  • 26. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new?
    Ariz U, Mato JM, Lu SC, Martínez Chantar ML.
    Methods Mol Biol; 2010 Jul; 593():109-36. PubMed ID: 19957147
    [Abstract] [Full Text] [Related]

  • 27. Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients.
    Valva P, De Matteo E, Galoppo M, Pedreira A, Giacove G, Lezama C, Marco I, Galoppo MC, Preciado MV.
    Hum Pathol; 2008 Dec; 39(12):1816-22. PubMed ID: 18715620
    [Abstract] [Full Text] [Related]

  • 28. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations.
    Preiss D, Sattar N.
    Clin Sci (Lond); 2008 Sep; 115(5):141-50. PubMed ID: 18662168
    [Abstract] [Full Text] [Related]

  • 29. The emerging problem of nonalcoholic steatohepatitis (NASH).
    Portincasa P, Grattagliano I, Palmieri VO, Palasciano G.
    Rom J Gastroenterol; 2005 Mar; 14(1):43-51. PubMed ID: 15800693
    [Abstract] [Full Text] [Related]

  • 30. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course.
    Cortez-Pinto H, Camilo ME.
    Best Pract Res Clin Gastroenterol; 2004 Dec; 18(6):1089-104. PubMed ID: 15561640
    [Abstract] [Full Text] [Related]

  • 31. Natural history of nonalcoholic steatohepatitis.
    Liou I, Kowdley KV.
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S11-6. PubMed ID: 16540761
    [Abstract] [Full Text] [Related]

  • 32. The histologic spectrum of nonalcoholic fatty liver disease.
    Contos MJ, Choudhury J, Mills AS, Sanyal AJ.
    Clin Liver Dis; 2004 Aug; 8(3):481-500, vii. PubMed ID: 15331059
    [Abstract] [Full Text] [Related]

  • 33. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease.
    Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, Yerian L, Zein NN, Feldstein AE.
    Liver Int; 2012 Feb; 32(2):297-302. PubMed ID: 22097893
    [Abstract] [Full Text] [Related]

  • 34. [Management of asymptomatic elevated serum aminotransferase levels, particularly in nonalcoholic steatohepatitis].
    Oldenburg B, Van Berge Henegouwen GP.
    Ned Tijdschr Geneeskd; 1999 Mar 06; 143(10):506-9. PubMed ID: 10321258
    [Abstract] [Full Text] [Related]

  • 35. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis.
    Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH.
    Liver Int; 2010 Jul 06; 30(6):795-808. PubMed ID: 20624207
    [Abstract] [Full Text] [Related]

  • 36. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome.
    Boppidi H, Daram SR.
    Postgrad Med; 2008 Jul 31; 120(2):E01-7. PubMed ID: 18654060
    [Abstract] [Full Text] [Related]

  • 37. Nonalcoholic steatohepatitis: risk factors and diagnosis.
    Adams LA, Feldstein AE.
    Expert Rev Gastroenterol Hepatol; 2010 Oct 31; 4(5):623-35. PubMed ID: 20932147
    [Abstract] [Full Text] [Related]

  • 38. Long-term prognosis of nonalcoholic fatty liver disease: is pharmacological therapy actually necessary?
    Cinar K, Coban S, Idilman R, Tuzun A, Sarioglu M, Bektas M, Erden E, Bozkaya H, Ozden A.
    J Gastroenterol Hepatol; 2006 Jan 31; 21(1 Pt 1):169-73. PubMed ID: 16706829
    [Abstract] [Full Text] [Related]

  • 39. Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis.
    Chen C, Schmilovitz-Weiss H, Liu XE, Pappo O, Halpern M, Sulkes J, Braun M, Cohen M, Barak N, Tur-Kaspa R, Vanhooren V, Van Vlierberghe H, Libert C, Contreras R, Ben-Ari Z.
    J Proteome Res; 2009 Feb 31; 8(2):463-70. PubMed ID: 19140676
    [Abstract] [Full Text] [Related]

  • 40. Histopathology of pediatric nonalcoholic fatty liver disease.
    Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, Lavine JE.
    Hepatology; 2005 Sep 31; 42(3):641-9. PubMed ID: 16116629
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.